Invuity (IVTY) vs. Motus GI (MOTS) Financial Analysis

Invuity (NASDAQ:IVTY) and Motus GI (NASDAQ:MOTS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Invuity and Motus GI’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Invuity N/A N/A N/A N/A N/A
Motus GI $10,000.00 5,224.77 -$13.20 million ($1.28) -2.60

Invuity has higher earnings, but lower revenue than Motus GI.

Profitability

This table compares Invuity and Motus GI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invuity N/A N/A N/A
Motus GI N/A -151.96% -114.68%

Insider & Institutional Ownership

55.3% of Invuity shares are held by institutional investors. Comparatively, 22.3% of Motus GI shares are held by institutional investors. 8.4% of Invuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Invuity and Motus GI, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invuity 0 5 0 0 2.00
Motus GI 0 0 5 0 3.00

Invuity currently has a consensus price target of $5.50, indicating a potential downside of 25.58%. Motus GI has a consensus price target of $10.50, indicating a potential upside of 215.32%. Given Motus GI’s stronger consensus rating and higher possible upside, analysts plainly believe Motus GI is more favorable than Invuity.

About Invuity

Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit